Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen.

ABSTRACT:

Background

The triplet combination of chemotherapy (docetaxel), androgen receptor pathway inhibitors (ARPI), and androgen deprivation therapy has recently become a recommended approach to treat metastatic castration-sensitive prostate cancer (mCSPC). This study aimed to compare the incremental time and cost burden of adding docetaxel to ARPI-based treatment among patients with mCSPC receiving chemotherapy-containing regimens (CCR) and non-chemotherapy-containing regimens (NCR) in the United States.

Methods

Clinical data from community urology practices linked with claims data (1/1/2016-12/31/2023) were used to select patients initiating a CCR or NCR. Outcomes, including time spent managing mCSPC (days with prostate cancer-related resource utilization or management care) and

SUBMITTER: Sentana-Lledo D 

PROVIDER: S-EPMC12512215 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature